Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immunogenicity of the recombinant trivalent poliomyelitis vaccine (Sf-RVN Cell) in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Sf-RVN Cell Recombinant Trivalent Poliomyelitis Vaccine (Recombinant trivalent poliovirus vaccine)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Poliomyelitis | Phase 1 | Status: COMPLETED